MEDICREA specializes in bringing pre-operative digital planning and pre and post-operative analytical services to the world of complex spine. Through the lens of predictive medicine, MEDICREA leads the design, integrated manufacture, and distribution of 30+ FDA approved implant technologies, utilized in over 100k spinal surgeries to date. Operating in a $10 billion marketplace, MEDICREA is an SME with 150 employees worldwide, which includes 55 at its USA Corp. subsidiary in NYC. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D-printed titanium patient-specific implants.
By leveraging its proprietary software analysis tools with big data and deep learning technologies supported by an expansive collection of clinical and scientific data, MEDICREA is well-placed to streamline the efficiency of spinal care, reducing procedural complications and limiting time spent in the O.R.Events December 15, 2016. KOL Investor Meeting at 08:00 EST. Contact Investor Relations for more information. Join webcast.
Chief Financial Officer
Tel: +33 (0)4 72 01 87 87
Chairman of the Board of Directors and Chief Executive Officer
Co-founder of MEDICREA
Mr Sournac comes from a purely scientific and medical background. With over 30 years’ experience in orthopaedics, notably in the retail of orthopaedic supplies. Denys Sournac was the man behind the 2002 merger of MEDICREA Technologies and ORSCO International, which gave rise to the MEDICREA Group in its current form. Mission: To expand MEDICREA, hold responsibility for the organisation and management of the Group and define its global strategy.
Chief Commercial and Business Development Officer
A successful spine executive with over 25 years of experience bringing with him a deep network in the World-Wide Spine Markets, Mr Kienzle is a Founder and served as the Executive Vice President Global Sales and Marketing of Globus Medical, Inc. (Ticker symbol GMED) until 2011. During Mr Kienzle’s tenure, Globus was widely noted as the fastest growing company in orthopedic history. GMED closed a $110M private placement with Goldman Sachs and Clarus Ventures in 2007 and an IPO with Goldman and BOA in 2012. Prior to Globus, he held the position of Area Vice President at Synthes Spine where he was responsible for all sales and marketing functions at this top-performing enterprise with over $90M in annual revenue (30% compounded growth rate) and before that culminated his 8 years with United States Surgical Corp as the National Business Director. Mission: to oversee the commercial expansion of Medicrea’s patient-specific UNiD technology and personalized treatment modalities.
Educational background in management and finance. 25 years’ experience in finance, including over 10 years heading the finance divisions of listed companies. Mission: Financial management of the Group, coordination of finance teams within subsidiaries, in charge of relations with banks and market authorities, responsible for financial information released to market.
VP Product Development
Studied biomaterials and biomechanics at the Université de Technologie de Compiègne (UTC) Former R&D Director, Scient’x. 11 years’ experience in orthopaedics. Mission: To design, develop and monitor products in close association with opinion-leading surgeons. To conduct clinical studies.